Neuromyelitis Optica Spectrum Disorders (NMOSD)

Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.

Retrieved on: 
Monday, March 15, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Horizon Therapeutics, Finance, Mergers and acquisitions, NASDAQ, Companies, Economy, Neuromyelitis Optica Spectrum Disorders (NMOSD), UPLIZNA, Horizon

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (Viela).

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (Viela).
  • The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company, said Tim Walbert, chairman, president and chief executive officer, Horizon.
  • The acquisition was structured as a two-step cash tender offer for all the issued and outstanding shares of Viela common stock at a price of $53.00 per share.
  • As a result of the merger, Viela became an indirect wholly owned subsidiary of Horizon.

Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

Retrieved on: 
Monday, February 1, 2021
Health, Clinical trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Branches of biology, Nervous system, Neuroscience, Autoimmune diseases, Neuromyelitis optica spectrum disorder, Optic nerve, Nerve, Neuromyelitis Optica Spectrum Disorders (NMOSD), TEPEZZA, KRYSTEXXA, UPLIZNA, Horizon, Viela Bio, Inc.

The current Viela pipeline includes four therapeutic candidates currently in nine development programs.

Key Points: 
  • The current Viela pipeline includes four therapeutic candidates currently in nine development programs.
  • Horizon anticipates the transaction will reduce its adjusted EBITDA by approximately $140 million in 2021, nearly all of which is attributable to increased R&D investment.
  • Horizon intends to finance the transaction through $1.3 billion of external debt along with cash on hand.
  • NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord and brain stem.

Viela Bio Announces Publication in The Lancet of Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Friday, September 6, 2019
Research, Pharmaceutical, Publishing, Science, Cardiology, Biotechnology, Communications, FDA, Health, Monoclonal antibodies, Inebilizumab, Autoimmune diseases, Organ systems, Medical specialties, Immunology, Neuromyelitis optica, The Lancet, CD19, Multiple sclerosis, Neuromyelitis Optica Spectrum Disorders (NMOSD), Inebilizumab, N-MOmentum, Viela Bio

Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).

Key Points: 
  • Viela Bio today announced that peer-reviewed journal, The Lancet, has published results from its pivotal study of inebilizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).
  • This study provided key information on the safety and efficacy profile of inebilizumab monotherapy in NMOSD.
  • Inebilizumab is the first and only biologic to use CD19 as a target for B cell depletion in this devastating disease.
  • Continued Dr. Drappa: The results from this pivotal study are very encouraging, demonstrating the potential impact on patient care if inebilizumab is approved by the U.S. Food and Drug Administration.

Viela Bio Announces U.S. FDA Accepts for Review Inebilizumab Biologics License Application for Neuromyelitis Optica Spectrum Disorder

Retrieved on: 
Tuesday, August 27, 2019
Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Autoimmune diseases, Medicine, Organ systems, Medical specialties, Multiple sclerosis, Rare diseases, Neuromyelitis optica, Inebilizumab, Devic, NMO, Myelitis, Placebo, Neuromyelitis Optica Spectrum Disorders (NMOSD), Inebilizumab, N-MOmentum, Viela Bio

The safety and efficacy results provided in the application are from the pivotal N-MOmentum trial, the largest global, placebo-controlled study in NMOSD.

Key Points: 
  • The safety and efficacy results provided in the application are from the pivotal N-MOmentum trial, the largest global, placebo-controlled study in NMOSD.
  • In addition, inebilizumab impacted measurements of worsening disability, hospitalizations and new central nervous system MRI lesions.
  • NMOSD is a recently proposed unifying term for neuromyelitis optica (NMO) also known as Devics disease and related syndromes.
  • Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make.